Advances in mechanisms of drug resistance in gastric cancer

World Chinese Journal of Digestology

Volumn 17, Issue 26, 2009, Pages 2692-2699

  Wang, Jun Pu ^a   Li, Jing He ^a   Wang, Kuan Song ^a  

^a The First People s Hospital of Changde City)   (China)

Author keywords

Drug resistance; Gastric cancer; Tumor

Indexed keywords

BREAKPOINT CLUSTER REGION PROTEIN; BREAST CANCER RESISTANCE PROTEIN; DEATH RECEPTOR 5; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; FAS ANTIGEN; FAS LIGAND; FLUOROURACIL; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLYCOPROTEIN P; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PRION PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH3; PROTEIN P21; PROTEIN P53; RAS PROTEIN; SORCIN; SUPEROXIDE DISMUTASE; TENIPOSIDE; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

CANCER MORTALITY; CANCER PATIENT; CANCER RESISTANCE; CAUSE OF DEATH; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; REVIEW; STOMACH CANCER;

EID: 75149152927     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: 10.11569/wcjd.v17.i26.2692     Document Type: Review

References (75)

1. Albert C. Clinical aspects of gastric cancer. In: Rustgi AK, eds. Gastrointestinal cancer: Biology, diagnosis and therapy. Philadelphia: Lippincott Raven, 1995: 197-216
2. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003; 14 Suppl 2: ii31-ii36
3. Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol 2006; 12: 17-20
4. Lu JB, Sun XB, Dai DX, Zhu SK, Chang QL, Liu SZ, Duan WJ. Epidemiology of gastroenterologic cancer in Henan Province, China. World J Gastroenterol 2003; 9: 2400-2403
5. Sasako M. Principles of surgical treatment for curable gastric cancer. J Clin Oncol 2003; 21: 274s-275s
6. Roth AD. Chemotherapy in gastric cancer: a never ending saga. Ann Oncol 2003; 14: 175-177
7. Choi JH, Lim HY, Joo HJ, Kim HS, Yi JW, Kim HC, Cho YK, Kim MW, Lee KB. Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer 2002; 86: 1578-1585
8. Ludwig A, Dietel M, Lage H. Identification of differentially expressed genes in classical and atypical multidrug-resistant gastric carcinoma cells. Anticancer Res 2002; 22: 3213-3221
9. Kowalski P, Stein U, Scheffer GL, Lage H. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2. Cancer Gene Ther 2002; 9: 579-586
10. Chinese source
11. El-Osta A, Kantharidis P, Zalcberg JR, Wolffe AP. Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol Cell Biol 2002; 22: 1844-1857
12. Shiraki N, Okamura K, Tokunaga J, Ohmura T, Yasuda K, Kawaguchi T, Hamada A, Nakano M. Bromocriptine reverses P-glycoprotein-mediated multidrug resistance in tumor cells. Jpn J Cancer Res 2002; 93: 209-215
13. Walther W, Stein U, Schlag PM. Use of the human MDR1 promoter for heat-inducible expression of therapeutic genes. Int J Cancer 2002; 98: 291-296
14. Grant DF, Bessho T, Reardon JT. Nucleotide excision repair of melphalan monoadducts. Cancer Res 1998; 58: 5196-5200
15. Bunting KD. ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 2002; 20: 11-20
16. Gürel S, Yerci O, Filiz G, Dolar E, Yilmazlar T, Nak SG, Gülten M, Zorluoglu A, Memik F. High expression of multidrug resistance-1 (MDR-1) and its relationship with multiple prognostic factors in gastric carcinomas in patients in Turkey. J Int Med Res 1999; 27: 79-84
17. Yeh KH, Chen CL, Shun CT, Lin JT, Lee WJ, Lee PH, Chen YC, Cheng AL. Relatively low expression of multidrug resistance-1 (MDR-1) and its possible clinical implication in gastric cancers. J Clin Gastroenterol 1998; 26: 274-278
18. Alexander D, Yamamoto T, Kato S, Kasai S. Histopathological assessment of multidrug resistance in gastric cancer: expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein. Surg Today 1999; 29: 401-406
19. Takebayashi Y, Akiyama S, Natsugoe S, Hokita S, Niwa K, Kitazono M, Sumizawa T, Tani A, Furukawa T, Aikou T. The expression of multidrug resistance protein in human gastrointestinal tract carcinomas. Cancer 1998; 82: 661-666
20. Yin D, Xie D, Hofmann WK, Zhang W, Asotra K, Wong R, Black KL, Koeffler HP. DNA repair gene O6-methylguanine-DNA methyltransferase: promoter hypermethylat ion associated wi th decreased expression and G:C to A:T mutations of p53 in brain tumors. Mol Carcinog 2003; 36: 23-31
21. Andressoo JO, Hoeijmakers JH, Mitchell JR. Nucleotide excision repair disorders and the balance between cancer and aging. Cell Cycle 2006; 5: 2886-2888
22. Valentini AM, Armentano R, Pirrelli M, Caruso ML. Chemotherapeutic agents for colorectal cancer with a defective mismatch repair system: the state of the art. Cancer Treat Rev 2006; 32: 607-618
23. Torchilin VP. Drug targeting. Eur J Pharm Sci 2000; 11 Suppl 2: S81-S91
24. Willis M, Forssen E. Ligand-targeted liposomes. Adv Drug Deliv Rev 1998; 29: 249-271
25. Gregoriadis G, Senoir J, Poste G. Targeting of Druns with Synthetic Systems. London: Plenum Press, 1996: 209-219
26. Kusama M, Kubota T, Matsukura Y, Matsuno K, Ogawa S, Kanda Y, Iga T. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. Clin Chim Acta 2006; 368: 93-98
27. Tolomeo M, Simoni D. Drug resistance and apoptosis in cancer treatment: development of new apoptosis-inducing agents active in drug resistant malignancies. Curr Med Chem Anticancer Agents 2002; 2: 387-401
28. Elliott T, Sethi T. Integrins and extracellular matrix: a novel mechanism of multidrug resistance. Expert Rev Anticancer Ther 2002; 2: 449-459
29. Yang JM, Xu Z, Wu H, Zhu H, Wu X, Hait WN. Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res 2003; 1: 420-427
30. Zhou Y, Xu Y, Tan Y, Qi J, Xiao Y, Yang C, Zhu Z, Xiong D. Sorcin, an important gene associated with multidrug-resistance in human leukemia cells. Leuk Res 2006; 30: 469-476
31. Du J, Pan Y, Shi Y, Guo C, Jin X, Sun L, Liu N, Qiao T, Fan D. Overexpression and significance of prion protein in gastric cancer and multidrug-resistant gastric carcinoma cell line SGC7901/ADR. Int J Cancer 2005; 113: 213-220
32. Hao Z, Li X, Qiao T, Du R, Hong L, Fan D. CIAPIN1 confers multidrug resistance by upregulating the expression of MDR-1 and MRP-1 in gastric cancer cells. Cancer Biol Ther 2006; 5: 261-266
33. Nobili S, Landini I, Giglioni B, Mini E. Pharmacological st rategies for overcoming multidrug resistance. Curr Drug Targets 2006; 7: 861-879
34. Takara K, Sakaeda T, Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 2006; 12: 273-286
35. Meschini S, Calcabrini A, Monti E, Del Bufalo D, Stringaro A, Dolfini E, Arancia G. Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells. Int J Cancer 2000; 87: 615-628
36. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and cl inical relevance. Clin Pharmacol Ther 2004; 75: 13-33
37. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58
38. Stein U, Lage H, Jordan A, Walther W, Bates SE, Litman T, Hohenberger P, Dietel M. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells. Int J Cancer 2002; 97: 751-760
39. Lin HL, Liu TY, Wu CW, Chi CW. Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel. Br J Cancer 1999; 81: 416-422
40. Wallner J, Depisch D, Gsur A, Götzl M, Haider K, Pirker R. MDR1 gene expression and its clinical relevance in primary gastric carcinomas. Cancer 1993; 71: 667-671
41. Chinese source
42. Triller N, Korosec P, Kern I, Kosnik M, Debeljak A. Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemonaive patients and in relapsed disease. Lung Cancer 2006; 54: 235-240
43. Chinese source
44. Sauna ZE, Kim IW, Ambudkar SV. Genomics and the mechanism of P-glycoprotein (ABCB1). J Bioenerg Biomembr 2007; 39: 481-487
45. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-1654
46. Eid H, Mingfang L, Institoris E, Bodrogi I, Bak M. MRP expression of testicular cancers and its clinical relevance. Anticancer Res 2000; 20: 4019-4022
47. van Zanden JJ, Geraets L, Wortelboer HM, van Bladeren PJ, Rietjens IM, Cnubben NH. Structural requirements for the flavonoid-mediated modulation of glutathione S-transferase P1-1 and GS-X pump activity in MCF7 breast cancer cells. Biochem Pharmacol 2004; 67: 1607-1617
48. Marquardt D, Center MS. Involvement of vacuolar H(+) -adenosine triphosphatase activity in multidrug resistance in HL60 cells. J Natl Cancer Inst 1991; 83: 1098-1102
49. Chinese source
50. Chinese source
51. Chinese source
52. Chinese source
53. Endo K, Maehara Y, Ichiyoshi Y, Kusumoto T, Sakaguchi Y, Ohno S, Sugimachi K. Multidrug resistance-associated protein expression in clinical gastric carcinoma. Cancer 1996; 77: 1681-1687
54. Morrow CS, Peklak-Scott C, Bishwokarma B, Kute TE, Smitherman PK, Townsend AJ. Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mi toxantrone via glutathione-dependent drug efflux. Mol Pharmacol 2006; 69: 1499-1505
55. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, van Kalken CK, Slovak ML, de Vries EG, van der Valk P. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein- mediated multidrug resistance. Cancer Res 1993; 53: 1475-1479
56. Plaat BE, Molenaar WM, Sagrudny J, Bohle RM, Mastik MF, Hoekstra HJ, Van der Graaf WT, Hollema H, van den Berg E. The 16p11 breakpoint in myxoid liposarcomas might affect the expression of the LRP gene on 16p11.2 encoding the multidrug resistance associated major vault protein. Eur J Clin Invest 2000; 30: 447-453
57. Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ. The drug resistance-related protein LRP is the human major vault protein. Nat Med 1995; 1: 578-582
58. Flens MJ, Zaman GJ, van der Valk P, Izquierdo MA, Schroeijers AB, Scheffer GL, van der Groep P, de Haas M, Meijer CJ, Scheper RJ. Tissue distribution of the multidrug resistance protein. Am J Pathol 1996; 148: 1237-1247
59. Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EA, Scheper RJ. Lung resistance-related protein/ major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 2000; 12: 550-556
60. Yu DQ, Yi YF. [Expression and significance of MRP, GST-pi, Topo IIalpha, and LRP in gastric carcinoma] Ai Zheng 2003; 22: 496-499
61. Schuurhuis GJ, Broxterman HJ, de Lange JH, Pinedo HM, van Heijningen TH, Kuiper CM, Scheffer GL, Scheper RJ, van Kalken CK, Baak JP. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br J Cancer 1991; 64: 857-861
62. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998; 95: 15665-15670
63. Chinese source
64. Ross DD, Karp JE, Chen TT, Doyle LA. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 2000; 96: 365-368
65. Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD, Kohno S. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int J Cancer 2004; 108: 146-151
66. Leontiou C, Watters GP, Gilroy KL, Heslop P, Cowell IG, Craig K, Lightowlers RN, Lakey JH, Austin CA. Differential selection of acridine resistance mutations in human DNA topoisomerase IIbeta is dependent on the acridine structure. Mol Pharmacol 2007; 71: 1006-1014
67. Chinese source
68. Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S- transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Cancer Invest 2008; 26: 344-351
69. Chinese source
70. Chinese source
71. Naniwa J, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Shimada M, Shimogai R, Kawaguchi W, Sato S, Terakawa N. Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer. Int J Gynecol Cancer 2007; 17: 76-82
72. Wang W, Liu G, Zheng J. Human renal UOK130 tumor cells: a drug resistant cell line with highly selective over-expression of glutathione S-transferase-pi isozyme. Eur J Pharmacol 2007; 568: 61-67
73. Lo HW, Ali-Osman F. Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Curr Opin Pharmacol 2007; 7: 367-374
74. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005; 45: 51-88
75. Zhang D, Fan D. Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Rev Anticancer Ther 2007; 7: 1369-1378